SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ciphergen Biosystems(CIPH):
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (199)2/3/2004 6:12:06 PM
From: Biomaven  Read Replies (2) of 510
 
Thanks, tuck.

From that site:

An important new recent development we have announced publicly is that specifically for our clinical trial-based applications, we have switched our analysis to utilize a higher resolution mass spectrometer for all of our pattern generation. We now employ an ABI Hybrid Pulsar QqTOF instrument (Q-Star) fitted with a Ciphergen SELDI source such that we can use the same protein chip configuration as before. This decision was made after months of thorough evaluation. We based our decision on the following:

a. The current configuration of the Ciphergen PBSII and PBCIIc has too low mass resolution and too high mass drift for our specific needs. In our hands, even after extensive external calibration and controls day-to-day, week-to-week and machine-to-machine variance was uncontrolled. In short, we could not run the same sample on the same machine at a later date and have the spectra align correctly. We realize that in the future, this problem may be obviated by newer instrumentation, but at this time, the performance of the Ciphergen PBSII and PBSIIc is unacceptable for routine clinical analysis and testing in our hands. Of course, it is very important to realize that the Ciphergen instrument was originally designed for research use only and not claimed as a clinical diagnostic platform, and we continue to support it and applaud it as a very useful and enabling proteomic discovery tool.
b. The tremendous increase in resolution of the Q-Star ( >9000 at m/z 1500) compared to the Ciphergen instrument (~100 to 200) and increase in mass accuracy of the Q-Star (10 ppm) vs. the Ciphergen instrument (1000 ppm) has given us the opportunity to bin data such that the same intensities fall into the same "bucket" every day, every week and every machine. The goal is REPRODUCIBILITY.

Peter
(no current CIPH position)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News